A "restrictive" red blood cell transfusion threshold, hemoglobin concentration <7-8 g/dL, has long been recommended for most hospitalized patients including anemic patients with stable cardiovascular disease (CVD). Although no threshold recommendation is given for acute coronary syndromes (ACS), recent evidence suggests that "liberal" rather than "restrictive" transfusion strategies are associated with significantly improved safety for hospitalized patients with stable CVD and/or ACS. This finding suggests that previously available data were misinterpreted. Conclusions drawn from earlier transfusion trigger trials have been confounded by unintentional trial design and analysis flaws that have contributed to erroneous recommendations regarding the safety of a restrictive threshold. Subsequently, these conclusions have been incorporated into widely accepted guidelines and clinical practice. Management with a restrictive versus liberal (<10 g/dL) transfusion strategy increases the risk of new-onset ACS in CVD patients by about 2%. We estimate that since 2019, using hospital databases and a recent meta-analysis, this practice may have resulted in about 700 excess ACS events per year in orthopedic surgical patients. Given these findings, transfusion practices in other clinical conditions, particularly those derived from similar transfusion trigger trials, should be questioned. Restrictive and liberal transfusion policies merit a general reconsideration. Rather than a single numerical transfusion trigger, transfusion therapy should be personalized. Consideration of an individual patient's age, clinical status, and co-morbidities is integral to transfusing. To avoid making similar errors, future trials of transfusion therapy should determine common practices before study inception and incorporate them as a usual care "control" comparator arm into the trial design. Such studies should more reliably improve current transfusion practice.
Skip Nav Destination
Discussion|
September 18, 2024
Hemoglobin-based Transfusion Strategies for Cardiovascular - and Other Diseases: Restrictive, Liberal, or Neither?
Clinical Trials & Observations
Charles Natanson,
NIH Clinical Center, Bethesda, Maryland, United States
* Corresponding Author; email: cnatanson@cc.nih.gov
Search for other works by this author on:
Willard N. Applefeld,
Willard N. Applefeld
Duke University Medical Center, Durham, North Carolina, United States
Search for other works by this author on:
Harvey G Klein
Harvey G Klein
NIH, Bethesda, Maryland, United States
Search for other works by this author on:
Blood blood.2024025927.
Article history
Submitted:
June 27, 2024
Revision Received:
September 4, 2024
Accepted:
September 6, 2024
Citation
Charles Natanson, Willard N. Applefeld, Harvey G Klein; Hemoglobin-based Transfusion Strategies for Cardiovascular - and Other Diseases: Restrictive, Liberal, or Neither?. Blood 2024; blood.2024025927. doi: https://doi.org/10.1182/blood.2024025927
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal